Multicenter, Randomized, Parallel Group Efficacy and Safety Study for the Prevention of Venous Thromboembolism in Hospitalized Acutely Ill Medical Patients Comparing Rivaroxaban With Enoxaparin - MAGELLAN


The optimal duration of thromboprophylaxis and the acutely ill patient population most likely to benefit from extended thromboprophylaxis is not well characterized. The current trial sought to compare different durations of rivaroxaban with enoxaparin in these patients.